Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation

Plasminogen activator inhibitor-1 (PAI-1) is known to protect mice against cardiac fibrosis. It has been speculated that PAI-1 may regulate cardiac fibrosis by inactivating urokinase-type plasminogen activator (uPA) and ultimately plasmin (Pm) generation. However, the in vivo role of PAI-1 in inactivating uPA and limiting the generation of Pm during cardiac fibrosis remains to be established. The objective of this study was to determine if the cardioprotective effect of PAI-1 is mediated through its ability to directly regulate urokinase -mediated activation of plasminogen (Pg). An Angiotensin II (AngII)-aldosterone (Ald) infusion mouse model of hypertension was utilised in this study. Four weeks after AngII-Ald infusion, PAI-1-deficient (PAI-1−/−) mice developed severe cardiac fibrosis. However, a marked reduction in cardiac fibrosis was observed in PAI-1−/−/uPA−/− double knockout mice that was associated with reduced inflammation, lower expression levels of TGF-β and proteases associated with tissue remodeling, and diminished Smad2 signaling. Moreover, total ablation of cardiac fibrosis was observed in PAI-1−/− mice that express inactive plasmin (Pm) but normal levels of zymogen Pg (PAI-1−/−/PgS743A/S743A). Our findings indicate that PAI-1 protects mice from hypertension-induced cardiac fibrosis by inhibiting the generation of active Pm.

[1]  J. Michel,et al.  Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. , 1999, Cardiovascular research.

[2]  A. Ghosh,et al.  PAI‐1 in tissue fibrosis , 2012, Journal of cellular physiology.

[3]  G. Wolf,et al.  TGF-beta and fibrosis in different organs - molecular pathway imprints. , 2009, Biochimica et biophysica acta.

[4]  D. Vaughan,et al.  Pharmacological Inhibition and Genetic Deficiency of Plasminogen Activator Inhibitor-1 Attenuates Angiotensin II/Salt-Induced Aortic Remodeling , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[5]  P. Carmeliet,et al.  Plasminogen activator inhibitor-1 gene-deficient mice. I. Generation by homologous recombination and characterization. , 1993, The Journal of clinical investigation.

[6]  Andrew W. Taylor.  Review of the activation of TGF‐β in immunity , 2008, Journal of leukocyte biology.

[7]  C. Harrison,et al.  Two Distinct Regions of Latency-associated Peptide Coordinate Stability of the Latent Transforming Growth Factor-β1 Complex* , 2010, The Journal of Biological Chemistry.

[8]  Z. Kassiri,et al.  Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease , 2012, Fibrogenesis & tissue repair.

[9]  S. Rosenkranz,et al.  Alterations of β-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-β1 , 2002 .

[10]  A. Ghosh,et al.  Global Gene Expression Profiling in PAI-1 Knockout Murine Heart and Kidney: Molecular Basis of Cardiac-Selective Fibrosis , 2013, PloS one.

[11]  A. Saria,et al.  Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues , 1983, Journal of Neuroscience Methods.

[12]  F. Castellino,et al.  Abrogation of Plasminogen Activator Inhibitor-1-Vitronectin Interaction Ameliorates Acute Kidney Injury in Murine Endotoxemia , 2015, PloS one.

[13]  S. Khan,et al.  Quantification of active and total transforming growth factor-β levels in serum and solid organ tissues by bioassay , 2012, BMC Research Notes.

[14]  P. Carmeliet,et al.  Physiological consequences of loss of plasminogen activator gene function in mice , 1994, Nature.

[15]  D. Kass,et al.  Pivotal role of cardiomyocyte TGF-β signaling in the murine pathological response to sustained pressure overload. , 2011, The Journal of clinical investigation.

[16]  C. Lau,et al.  Smad3 Mediates Cardiac Inflammation and Fibrosis in Angiotensin II–Induced Hypertensive Cardiac Remodeling , 2010, Hypertension.

[17]  B. Klanke,et al.  Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage , 2011, Journal of hypertension.

[18]  S. Rosenkranz,et al.  Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). , 2002, American journal of physiology. Heart and circulatory physiology.

[19]  A. Ghosh,et al.  Genetic Deficiency of Plasminogen Activator Inhibitor-1 Promotes Cardiac Fibrosis in Aged Mice: Involvement of Constitutive Transforming Growth Factor-&bgr; Signaling and Endothelial-to-Mesenchymal Transition , 2010, Circulation.

[20]  L. Miles,et al.  PAI-1: cardiac friend or foe? , 2010, Blood.

[21]  A. Luttun,et al.  Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure , 1999, Nature Medicine.

[22]  D. Dichek,et al.  Overexpression of Urokinase by Macrophages or Deficiency of Plasminogen Activator Inhibitor Type 1 Causes Cardiac Fibrosis in Mice , 2004, Circulation research.

[23]  L. Field,et al.  Atrial but not ventricular fibrosis in mice expressing a mutant transforming growth factor-beta(1) transgene in the heart. , 2000, Circulation research.

[24]  F. Castellino,et al.  The generation and characterization of mice expressing a plasmin‐inactivating active site mutation , 2010, Journal of thrombosis and haemostasis : JTH.

[25]  S. Yuan,et al.  Cardiac pathologies in relation to Smad-dependent pathways. , 2010, Interactive cardiovascular and thoracic surgery.

[26]  T. Walz,et al.  Latent TGF-β structure and activation , 2011, Nature.

[27]  N. Frangogiannis,et al.  Transforming growth factor (TGF)-β signaling in cardiac remodeling. , 2011, Journal of molecular and cellular cardiology.

[28]  A. Eddy,et al.  Endogenous urokinase lacks antifibrotic activity during progressive renal injury. , 2007, American journal of physiology. Renal physiology.

[29]  F. Castellino,et al.  Plasminogen activator inhibitor-1 (PAI-1) is cardioprotective in mice by maintaining microvascular integrity and cardiac architecture. , 2010, Blood.

[30]  R. Kalluri,et al.  The origin of fibroblasts and mechanism of cardiac fibrosis , 2010, Journal of cellular physiology.

[31]  L. Gleaves,et al.  Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production , 2011, Journal of hypertension.